| Literature DB >> 26935030 |
Silvia Sookoian1, Gustavo O Castaño2, Romina Scian1,3, Julio San Martino4, Carlos J Pirola3.
Abstract
Ballooning degeneration (BD) of hepatocytes is a distinguishing histological feature associated with the progression of nonalcoholic fatty liver disease (NAFLD). Under the assumption that NAFLD severity is associated with metabolic-stress we explored the hypothesis that heat shock 27 kDa protein 1 (HSP27), a protein chaperone involved in stress resistance and cytoskeletal-remodeling, might be deregulated in ballooned hepatocytes. We observed that fasting plasma glucose (fpG) (p = 0.00002), total cholesterol (p = 0.02) and triglycerides (p = 0.01) levels, and female sex (p = 0.01) were significantly associated with the presence of BD. A logistic regression model showed that BD was independently associated with fpG (p = 0.002); OR per unit of glucose concentration 1.05, 95% confidence interval 1.02-1.09. Furthermore, BD was associated with a significant 2.24-fold decrease in the expression level of HSP27-mRNA in comparison with absence of ballooning, p = 0.002. Ballooned hepatocytes showed very low HSP27 immunoreactivity compared with hepatocyes without ballooning (p = 0.009); HSP27 immunoreactivity was inversely correlated with fpG levels (R: -0.49, p = 0.01). In conclusion, BD is associated with down-regulation of liver HSP27 gene and protein expression, suggesting that ballooned hepatocytes fail to ensure a robust physiological response to metabolic-induced stress.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26935030 PMCID: PMC4776115 DOI: 10.1038/srep22528
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Clinical and biochemical characteristics of the patients according to ballooning degeneration.
| Variable | Ballooning (0 = none) | Ballooning (1–2) | P value |
|---|---|---|---|
| Number of subjects | 143 | 113 | |
| Demographic and lifestyle factors | |||
| Male/Female, % | 59/51 | 30/70 | 0.01 |
| Age, years | 52.3 ± 11.7 | 50.7 ± 11.4 | NS |
| Physical activity, h/week | 1.2 ± 2.1 | 1.6 ± 6.0 | NS |
| Alcohol consumption, g/day | 17.5 ± 36 | 11.4 ± 26.6 | NS |
| Obesity and central obesity | |||
| BMI, kg/m2 | 31.7 ± 5.5 | 33.1 ± 6.2 | NS |
| Waist circumference, cm | 107 ± 12 | 108 ± 13 | NS |
| Waist/hip ratio | 0.97 ± 0.07 | 0.97 ± 0.07 | NS |
| Body fat content, % | 36 ± 8 | 38 ± 8 | NS |
| Abdominal wall thickness, mm | 49.5 ± 14 | 50.2 ± 14 | NS |
| Glucose metabolism | |||
| Fasting plasma glucose, mg/dl | 101 ± 23 | 122 ± 43 | 0.00002 |
| Fasting plasma insulin, mg/dl | 14.6 ± 8.6 | 15.4 ± 10 | NS |
| HOMA-IR index | 3.7 ± 2.4 | 4.6 ± 4 | NS |
| HbA1c, % | 6.6 ± 1.6 | 7.8 ± 2.7 | NS |
| Type 2 diabetes, % | 31 | 49 | 0.02 |
| Cardiovascular risk factors | |||
| SABP, mmHg | 125 ± 16 | 129 ± 16 | NS |
| DABP, mmHg | 78 ± 11 | 80 ± 11 | NS |
| Cardiovascular risk, % | 6.7 ± 9 | 6 ± 4 | NS |
| Total cholesterol/HDL cholesterol ratio | 3.7 ± 1.9 | 4 ± 1.9 | NS |
| C reactive protein | 5.7 ± 4 | 5.5 ± 4 | NS |
| Leukocyte count, cells/mm3 | 7375 ± 2354 | 7769 ± 1890 | NS |
| Total cholesterol, mg/dL | 199.5 ± 41 | 216 ± 45 | 0.02 |
| HDL-cholesterol, mg/dL | 51.5 ± 19 | 51.4 ± 13 | NS |
| LDL-cholesterol, mg/dL | 121 ± 39 | 129 ± 40 | NS |
| Triglycerides, mg/dL | 152 ± 75 | 191 ± 117 | 0.01 |
| Uric acid, mg/dL | 5.2 ± 1.9 | 5.2 ± 1.8 | NS |
| Liver phenotype | |||
| ALT, U/L | 58 ± 46 | 70 ± 49 | 0.06 |
| AST, U/L | 39 ± 20 | 48 ± 30 | 0.01 |
| GGT, U/L | 81 ± 87 | 73 ± 56 | NS |
| AP, U/L | 236 ± 107 | 193 ± 94 | 0.001 |
| Total bilirubin, mg/dL | 0.7 ± 0.3 | 0.7 ± 0.4 | NS |
| CK-18 | 258 ± 270 | 307 ± 295 | NS |
Ballooning (0 = none; 1 = rare or few; 2 = many). Results are expressed as mean ± SD.; P value stands for statistical significance using the Mann–Whitney U test except where #indicates the P value for a Pearson Chi square test. NS: non significant.
BMI: body mass index; SABP and DABP: systolic and diastolic arterial blood pressure, respectively; HOMA-IR: homeostatic model assessment-insulin resistance; ALT and AST: serum alanine and aspartate aminotransferase; GGT: gamma-glutamyl-transferase; AP: alkaline phosphatase. *Risk for developing coronary heart disease outcomes using Framingham risk scoring.
&Caspase-generated CK-18 fragment (CK-18): Caspase-generated CK-18 fragment (CK-18)—a noninvasive quantification of hepatocellular apoptosis—concentration was measured by the one-step in vitro immunoassay M30-apoptosense ELISA kit (PEVIVA AB; DiaPharma, OH, USA) that recognizes selectively the caspase cleavage generated against the K18Asp396 neoepitope of CK-18.
Multiple logistic regression used to determine the independent associations of variables with the presence of ballooning degeneration.
| Sex | Diabetes | fPG | COL | AST | AP | |
|---|---|---|---|---|---|---|
| p-level | 0.12 | 0.42 | 0.002 | 0.10 | 0.75 | 0.009 |
| Odds ratio (unit ch) | 0.307 | 0.550 | 1.050 | 18.280 | 1.182 | 0.117 |
| −95%CL | 0.066 | 0.125 | 1.020 | 0.516 | 0.396 | 0.0225 |
| +95%CL | 1.425 | 2.413 | 1.090 | 646.513 | 3.531 | 0.607 |
fPG: Fasting plasma glucose, mg/dl; COL: Total cholesterol, mg/dL; AST: serum aspartate aminotransferase; AP: alkaline phosphatase.
Figure 1ROC curve analysis of the performance of plasma fasting glucose levels in predicting hepatocellular ballooning.
The ROC analysis by main predictors associated with histologic disease progression, such as plasma fasting glucose and insulin levels, ALT, AST, and abdominal obesity evaluated as waist circumference was adjusted by body mass index. The figure indicates ROC curve analysis of the performance of plasma fasting glucose levels in predicting hepatocellular ballooning; our results show that glucose performed better than ALT, AST, waist circumference, and plasma fasting insulin levels in predicting ballooning degeneration (fPG vs. ALT p = 0.12, vs. AST p = 0.20, vs. WC p = 0.04, vs. fPI p = 0.05). fPG: fasting plasma glucose, fPI: fasting plasma insulin, TPR: true positive rate, FPR: false positive rate.
Figure 2Liver expression of HSP27 is down-regulated in ballooned hepatocytes.
Bars represent immunoreactivity scores of HSP27 staining; mean ± SD values. (A) Representative liver expression pattern of HSP27 in a NAFLD patient without ballooning degeneration; black arrows indicate HSP27 immunoreactivity in hepatocyte cytoplasm or surrounding the lipid droplets showing a granular pattern. (B) Representative liver expression pattern of HSP27 in a patient with NASH and ballooning degeneration. (C) Representative liver expression pattern of HSP27 in focal areas of marked ballooning degeneration (C1) or absence of ballooning (C2) in the same liver specimen of a patients with NAFLD. BH: ballooned hepatocytes (enlarged hepatocytes with pale to clear cytoplasm, some of them showing glycogenated nuclei GN); LD: lipid droplet. Protein expression was explored using immunohistochemistry; ballooning degeneration was dichotomized to: ballooning 0 (none) versus ballooning 1 (mild or marked). HSP27 immunoreactivity was examined using light microscopy of liver sections; counterstaining was performed with hematoxylin. Original magnification: 400X.
Primer sequences used for mRNA expression analysis.
| Gene official name | HGNC Symbol Entrez Gene Ensembl number | Forward primer 5′→3′ | Reverse primer 5′→3′ |
|---|---|---|---|
| Ribosomal Protein L19 | AAAACAAGCGGATTCTCATGGA | TGCGTGCTTCCTTGGTCTTAG | |
| Heat Shock 27kDa Protein 1 | ACGGTCAAGACCAAGGATGG | AGCGTGTATTTCCGCGTGA |